Fundraising FoxThird Rock Ventures — 2023 Investments
6 investments dated 2023 · listed companies and verified rows first · show all
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.
BiotechBoston, US
Alan Huang(Executive Officer)inAdam Crystal(Executive Officer)inDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)
BoardBarbara Weber(Executive Officer, Director)in
Board seatAlexis BorisyReid Huber· per SEC Form D
Co-investorsForesite CapitalNextech InvestNSG VenturesRoche Venture Fund
Rapport is a biopharmaceutical company developing novel therapeutics.
BiotechHealthtechMedical Devices
Abe Ceesay(President)Cheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)Steven Paul David Bredt(Founder)
Co-investorsARCH Venture PartnersSofinnova VenturesCapital GroupJohnson & Johnson Innovation – JJDC
Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in
Board seatJeffrey Tong· per SEC Form D
Co-investorsCatalio Capital Management, LPRA CapitalSamsara BioCapitalVertex Ventures HC
A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.
BiotechDeep TechMedical DevicesWilmington, US
Liangxing Wu(Executive Officer, Director)inWenqing Yao(Executive Officer, Director)inTing Feng(Director)Wenqing Yao, Ph.D.(Founder & CEO)Liangxing Wu, Ph.D.(Co-Founder & SVP Drug Discovery)
Board seatReid Huber· per SEC Form D
Co-investorsNextech InvestThe Innovation Space
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsNextech InvestRed Tree VentureSamsara BioCapitalWellington ManagementAlly Bridge GroupJanus Henderson Investors+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.